Bright Minds Biosciences (DRUG) Invested Capital (2022 - 2026)

Bright Minds Biosciences has reported Invested Capital for 5 years, with the latest figure at $266.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 325.75% year-over-year to $266.7 million; the trailing twelve-month figure through Mar 2026 stood at $266.7 million (up 325.75% YoY), and the FY2025 full-year result was $89.6 million, up 244.89% from the prior year.
• Invested Capital for Q1 2026 stood at $266.7 million, up from $98.1 million in the prior quarter.
• The five-year high for Invested Capital was $266.7 million in Q1 2026, with the low at $4.9 million in Q3 2023.
• Historically, Invested Capital has averaged $66.9 million across 5 years, with a median of $62.6 million in 2025.
• Annual changes were most pronounced in 2023 — Invested Capital sank 39.11% — and 2024, when it surged 427.59%.
• Bright Minds Biosciences' Invested Capital stood at $8.1 million in 2022, then jumped by 218.47% to $25.7 million in 2023, then jumped by 147.54% to $63.7 million in 2024, then surged by 53.91% to $98.1 million in 2025, then surged by 171.96% to $266.7 million in 2026.
• The last three Invested Capital figures came in at $266.7 million (Q1 2026), $98.1 million (Q4 2025), and $89.6 million (Q3 2025), per Business Quant data.